Mark McClellan, MD, PhD, director, Engelberg Center for Health Care Reform, Leonard D. Schaeffer Chair in Health Policy Studies, Brookings Institution, says that getting the best possible benefits of the healthcare system at the lowest cost is what really matters to patients.
Mark McClellan, MD, PhD, director, Engelberg Center for Health Care Reform, Leonard D. Schaeffer Chair in Health Policy Studies, Brookings Institution, says getting the best possible benefits of the healthcare system at the lowest cost is what matters to patients.
Dr McClellan also says that, "we will be seeing Increasing changes in delivery and increasing changes in financing to go along with it."
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More